BMS-354825

Indications: -> chronic myeloid leukemia (CML) Mechanism of action: 1) inhibits bcl-abl that stimulates proliferation of abnormal leukocytes 2) binds to different site than imatinib 3) effective in 14 of 15 imatinab-resistant tumors

General

antineoplastic agent (chemotherapeutic agent) protein kinase inhibitor

References

Journal Watch 24(18):124, 2004 Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004 Jul 16;305(5682):399-401. PMID: 15256671